Ann: Phelan-McDermid Syndrome & CNS platform presentation, page-30

He doesn’t think it’s a critical market sensitive milestone, but as a retail shareholder with a simple mind; it upgrades us to a new category within the industry and hopefully we’ll get some renewed recognition of dosing our molecules in humans instead of in the lab/animals. This recognition will hopefully be two fold - sharemarkets and industry.

But I will take his advice hint/advice to back off from sweating the small stuff and let the team get on with the excellent science and potential of the platform - which is the reason why we are all still here

Rohan said it has been the best 6 months of scientific breakthroughs they had - will check back with you all at the AGM!